ANDA Litigation Settlements - First Quarter 2026

Multiple ANDA litigation settlements resolved in Q1 2026 across federal courts. Major pharmaceutical companies including Pfizer, Astellas, Boehringer Ingelheim, Janssen, and Bayer settled patent disputes with generic manufacturers like Teva, Lupin, Hikma, and others. Settlements typically involved admissions of patent validity and infringement, injunctions preventing generic entry until patent expiration, and dismissal of all claims with prejudice. Key drugs included Jardiance, Xarelto, Myrbetriq, Wakix, and Caplyta. Parties generally bore own attorneys' fees.